IgE-mediated chlorhexidine allergy-Cross-reactivity with other biguanide disinfectants.

IgE ImmunoCAP alexidine allergy anaphylaxis basophil activation test biguanide disinfectants chlorhexidine cross-reactivity octenidine polyhexanide

Journal

Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028

Informations de publication

Date de publication:
12 2020
Historique:
received: 27 03 2020
revised: 30 04 2020
accepted: 05 05 2020
pubmed: 18 7 2020
medline: 15 5 2021
entrez: 18 7 2020
Statut: ppublish

Résumé

Chlorhexidine (CHX) is a widely utilized disinfectant that can cause IgE-mediated urticaria/anaphylaxis. The cross-reactivity of patients with IgE-mediated CHX allergy with other disinfectants, which share structural similarities with CHX like polyhexanide (polyhexamethylene biguanide; PHMB), alexidine (ALX), or octenidine (OCT), is unknown. Forty-four patients with anaphylaxis or urticaria upon CHX exposure and positive skin prick test (SPT) and/or positive CHX ImmunoCAP test (Phadia TFS, Uppsala, Sweden) were recruited. IgE to the biguanide and/or hexamethylene structure was investigated with PHMB ImmunoCAP (n = 32) and by basophil activation tests (BAT) with CHX and ALX (n = 37). Inhibition tests of CHX and PHMB ImmunoCAPs by CHX, ALX, PHMB, and OCT were performed. IgE reactivity to PHMB as surrogate marker for biguanide/hexamethylene reactivity was detected in 5/32 sera. Seven of 37 patients showed a positive BAT with ALX, but only under optimized conditions. Binding to CHX ImmunoCAP was inhibited by ALX in 1/32 sera, and binding to PHMB was blocked by ALX (1/5) and by OCT in another (1/5). In SPT, 9/10 patients were positive for CHX and 3 of them with ALX (only at highest concentration at 5 mg/mL). A further patient reacted primarily with OCT and showed IgE cross-reactivity with CHX, ALX, and PHMB. The IgE response to CHX seems polyclonal. The chloroguanide ending of CHX is the main epitope for the IgE and is suitable as screening assay to detect CHX reactivity. IgE-reactivities with the biguanide or hexamethylene components of other disinfectants (ALX, PHMB) can be detected by SPT, PHMB ImmunoCAP, and ALX-BAT in 15%-33% of CHX-allergic patients.

Sections du résumé

BACKGROUND
Chlorhexidine (CHX) is a widely utilized disinfectant that can cause IgE-mediated urticaria/anaphylaxis. The cross-reactivity of patients with IgE-mediated CHX allergy with other disinfectants, which share structural similarities with CHX like polyhexanide (polyhexamethylene biguanide; PHMB), alexidine (ALX), or octenidine (OCT), is unknown.
METHODS
Forty-four patients with anaphylaxis or urticaria upon CHX exposure and positive skin prick test (SPT) and/or positive CHX ImmunoCAP test (Phadia TFS, Uppsala, Sweden) were recruited. IgE to the biguanide and/or hexamethylene structure was investigated with PHMB ImmunoCAP (n = 32) and by basophil activation tests (BAT) with CHX and ALX (n = 37). Inhibition tests of CHX and PHMB ImmunoCAPs by CHX, ALX, PHMB, and OCT were performed.
RESULTS
IgE reactivity to PHMB as surrogate marker for biguanide/hexamethylene reactivity was detected in 5/32 sera. Seven of 37 patients showed a positive BAT with ALX, but only under optimized conditions. Binding to CHX ImmunoCAP was inhibited by ALX in 1/32 sera, and binding to PHMB was blocked by ALX (1/5) and by OCT in another (1/5). In SPT, 9/10 patients were positive for CHX and 3 of them with ALX (only at highest concentration at 5 mg/mL). A further patient reacted primarily with OCT and showed IgE cross-reactivity with CHX, ALX, and PHMB.
CONCLUSION
The IgE response to CHX seems polyclonal. The chloroguanide ending of CHX is the main epitope for the IgE and is suitable as screening assay to detect CHX reactivity. IgE-reactivities with the biguanide or hexamethylene components of other disinfectants (ALX, PHMB) can be detected by SPT, PHMB ImmunoCAP, and ALX-BAT in 15%-33% of CHX-allergic patients.

Identifiants

pubmed: 32678912
doi: 10.1111/all.14497
doi:

Substances chimiques

Biguanides 0
Disinfectants 0
Immunoglobulin E 37341-29-0
Chlorhexidine R4KO0DY52L

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3237-3247

Informations de copyright

© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Références

Calogiuri GF, Di Leo E, Trautmann A, et al. Chlorhexidine hypersensitivity: a critical and updated review. J Allergy Ther. 2013;4:141.
Garvey LH, Roed-Petersen J, Husum B. Anaphylactic reactions in anaesthetised patients - four cases of chlorhexidine allergy. Acta Anaesthesiol Scand. 2001;45:1290-1294.
Wicki J, Deluze C, Cirafici L, Desmeules J. Anaphylactic shock induced by intraurethral use of chlorhexidine. Allergy. 1999;54(7):768-769.
Ljunggren B, Möller H. Eczematous contact allergy to chlorhexidine. Acta Derm Venereol. 1972;52(4):308-310.
Opstrup MS, Johansen JD, Garvey LH. Chlorhexidine allergy: sources of exposure in the health-care setting. Br J Anaesth. 2015;114(4):704-705.
Ebo DG, Van Gasse AL, Decuyper II, et al. Acute management, diagnosis, and follow-up of suspected perioperative hypersensitivity reactions in Flanders 2001-2018. J Allergy Clin Immunol Pract. 2019;7(7):2194-2204.e7.
Layton GT, Stanworth DR, Amos HE. The incidence of IgE and IgG antibodies to chlorhexidine. Clin Exp Allergy. 1989;19:307-314.
Nagendran V, Wicking J, Ekbote A, Onyekwe T, Garvey L. IgE-mediated chlorhexidine allergy: a new occupational hazard? Occup Med. 2009;59(4):270-272.
Pham NH, Weiner JM, Reisner GS, Baldo BA. Anaphylaxis to chlorhexidine. Case report. Implication of immunoglobulin E antibodies and identification of an allergenic determinant. Clin Exp Allergy. 2000;30(7):1001-1007.
Schrøder MA, Kirketerp-Møller K, Winther L. Suspected anaphylaxis by wound treatment with polyhexanide derivate wound products. Ugeskr Laeger. 2014;176(25A):V02120094.
Schunter JA, Stöcker B, Brehler R. A case of severe anaphylaxis to polyhexanide: cross-reactivity between biguanide antiseptics. Int Arch Allergy Immunol. 2017;173(4):233-236.
Kautz O, Schumann H, Degerbeck F, Venemalm L, Jakob T. Severe anaphylaxis to the antiseptic polyhexanide. Allergy. 2010;65(8):1068-1070.
Olivieri J, Eigenmann PA, Hauser C. Severe anaphylaxis to a new disinfectant: polyhexanide, a chlorhexidine polymer. Schweiz Med Wochenschr. 1998;128(40):1508-1511.
Calow T, Oberle K, Bruckner-Tuderman L, Jakob T, Schumann H. Contact dermatitis due to use of Octenisept in wound care. J Dtsch Dermatol Ges. 2009;7(9):759-765.
Bubenhofer M, Fricker M, Weber-Mani U, Helbling A. Chlorhexidine: a retrospective observational study of a potentially life-threatening molecule. J Investig Allergol Clin Immunol. 2015;25(2):152-154.
Garvey LH, Krøigaard M, Poulsen LK, et al. IgE-mediated allergy to chlorhexidine. J Allergy Clin Immunol. 2007;120(2):409-415.
Bischoff SC, de Weck AL, Dahinden CA. Interleukin 3 andgranulocyte/macrophage-colony-stimulating factor render human basophilsresponsive to low concentrations of complement component C3a. Proc Natl Acad Sci USA. 1990;87(17):6813-6817.
Steiner UC, Gentinetta T, Hausmann O, Pichler WJ. IgE-mediated anaphylaxis to intraarticular glucocorticoid. Am J Roentgenol. 2009;193(2):W156-W157.
Pruzansky JJ, Grammer LC, Patterson R, Roberts M. Dissociation of IgE from receptors on human basophils. I. Enhanced passive sensitization for histamine release. J Immunol. 1983;131:1949-1953.
Yasui K, Matsuyama N, Okamura-Shiki I, et al. Clinical utility of a passive immune basophil activation test for the analysis of allergic transfusion reactions. Transfusion. 2017;57(9):2084-2095.
Van der Poorten MM, Van Gasse AL, Hagendorens MM, et al. Serum specific IgE antibodies in immediate drug hypersensitivity. Clin Chim Acta. 2020;504:119-124.
Ebo DG, Bridts CH, Mertens CH, Hagendorens MM, Stevens WJ, De Clerck LS. Analyzing histamine release by flow cytometry (HistaFlow): a novel instrument to study the degranulation patterns of basophils. J Immunol Methods. 2012;375(1-2):30-38.
Spoerl D, Jandus P, Harr T. Pitfalls and peculiarities in chlorhexidine allergy. J Allergy Clin Immunol Pract. 2016;5:991-992.

Auteurs

Nicole Mueller-Wirth (N)

ADR-AC GmbH, Bern, Switzerland.

Antonia Buenter (A)

ADR-AC GmbH, Bern, Switzerland.
Dep. of Rheumatology, Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland.

Lukas Jörg (L)

Dep. of Rheumatology, Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland.

Didier G Ebo (DG)

Department of Immunology - Allergology - Rheumatology and the Infla-Med Centre of Excellence, University Antwerp, Antwerp University Hospital, Antwerpen, Belgium.

Martin Glatz (M)

Allergiestation, University of Zurich, Zurich, Switzerland.

Suran L Fernando (SL)

Faculty of Medicine and Health (Immunology and Infectious Diseases), University of Sydney, Sydney, NSW, Australia.

David Spoerl (D)

Department of Clinical Immunology and Allergy, HUG Geneva, Geneva, Switzerland.

Arthur Helbling (A)

Dep. of Rheumatology, Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland.

Oliver Hausmann (O)

ADR-AC GmbH, Bern, Switzerland.
Löwenpraxis, Lucerne, Switzerland.

Nisha Gupta (N)

Teleflex Inc., Reading, PA, USA.

Werner J Pichler (WJ)

ADR-AC GmbH, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH